A new era for pharmaceutical cases in China: we start to see winning patent linkage cases enforcing the rights of international companies such as AstraZeneca v Sichuan Gowell, Chugai Pharma v Ouyi. In infringement cases: Boehringer Ingelheim v Sunshine Lake and a few more. Administrative enforcement action is the popular route nowadays. The statistic below is by no mean complete because China Judgment Online only contains some but far from all of the effective judgments. But it is definitely a change of scene from the half-Bolar ice age pre-2021.
Christine Yiu’s Post
More Relevant Posts
-
#Patent #Novo_Nordisk vs #Generic_drug_makers Novo Nordisk, the maker of the popular weight-loss drug Wegovy, is currently embroiled in a patent dispute as it seeks to fend off competition from generic drug makers. Companies like Sun Pharma from India and Mylan Pharmaceuticals from West Virginia are attempting to gain FDA approval to produce generic versions of Wegovy. Novo Nordisk has responded by filing patent infringement claims, arguing that these efforts violate its intellectual property rights. This legal battle underscores the pharmaceutical industry's high stakes in protecting profitable drugs from generic competition, especially as demand for weight-loss remedies like Wegovy surges. #medicine #weight #loss #remedies #generic #entrepreneur #business #legal #china #legal #linkedin #voice #europe NyayaSarthak FinancialBIA
To view or add a comment, sign in
-
In GCR’s Americas Antitrust Review 2025, White & Case’s competition lawyers discuss the latest pharmaceutical antitrust developments, including reverse payment cases, product hopping, and pricing practices. Read more here. https://ow.ly/Qzp050T1JH7
To view or add a comment, sign in
-
In GCR’s Americas Antitrust Review 2025, White & Case’s competition lawyers discuss the latest pharmaceutical antitrust developments, including reverse payment cases, product hopping, and pricing practices. Read more here. https://ow.ly/it1j50T1HE1
United States: Pharmaceutical Antitrust 2025 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
Novo Nordisk has long dominated the GLP-1 receptor market, but as generic competitors challenge their patents, the stakes are higher than ever. In his recent article for Law360, Pedram Sameni—Patexia’s CEO and an expert in the intellectual property landscape—delves into Novo Nordisk’s legal defense strategies, focusing on ANDA litigation, patent challenges, and the risks in this multibillion-dollar battle. 💡 Key Takeaways: ◾ With 37 patents protecting blockbuster drugs like Ozempic and Wegovy, Novo Nordisk is under mounting legal pressure as the Type 2 diabetes and obesity treatment market expands. ◾ Competitors like Viatris and Sun Pharma are using ANDA litigation and IPR filings to challenge patent validity, which could reshape the market landscape. ◾ A loss could mean billions in revenue, with up to 70-80% of market share slipping to generics within the first year of their entry. 📖 To uncover the legal strategies behind one of the most significant pharmaceutical battles of today, read the full article. #PatentLaw #ANDA #IPR #Pharmaceuticals #NovoNordisk #LegalInsights #IPTrends #PatentLitigation
To view or add a comment, sign in
-
In GCR’s Americas Antitrust Review 2025, White & Case’s competition lawyers discuss the latest pharmaceutical antitrust developments, including reverse payment cases, product hopping, and pricing practices. Read more here. https://ow.ly/aeLz50T1B3X
United States: Pharmaceutical Antitrust 2025 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
In GCR’s Americas Antitrust Review 2025, White & Case’s competition lawyers discuss the latest pharmaceutical antitrust developments, including reverse payment cases, product hopping, and pricing practices. Read more here. https://ow.ly/vCJu50T1Fez
United States: Pharmaceutical Antitrust 2025 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
In GCR’s Americas Antitrust Review 2025, White & Case’s competition lawyers discuss the latest pharmaceutical antitrust developments, including reverse payment cases, product hopping, and pricing practices. Read more here. https://ow.ly/lCp550T4uwF
United States: Pharmaceutical Antitrust 2025 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
In GCR’s Americas Antitrust Review 2025, White & Case’s competition lawyers discuss the latest pharmaceutical antitrust developments, including reverse payment cases, product hopping, and pricing practices. Read more here. https://ow.ly/Cr5S50T1ZUj
United States: Pharmaceutical Antitrust 2025 | White & Case LLP
whitecase.com
To view or add a comment, sign in
-
In a recent ruling, the European Union Court has upheld a fine of €13.96 million (approximately Rs 125.62 crore) on Ipca Laboratories’ subsidiaries, Unichem and Niche Generics, related to a patent dispute settlement agreement with the Servier group. Key Details: - Entities Involved: Unichem Laboratories Ltd and Niche Generics Ltd, subsidiaries of Ipca Laboratories. - Dispute Background: The fine pertains to a settlement agreement over the Perindopril drug patent with Servier, a French pharmaceutical company. - Patent History: Perindopril, used for treating hypertension and heart failure, had its patent challenged by multiple companies, including Unichem and Niche. - Allegation: It was alleged that the settlement agreement breached EU competition law. Financial Impact: - Fine Amount: €13.96 million (approximately Rs 125.62 crore). - Provision Made: Ipca Labs and Unichem have already made provisions for the fine in their financial statements. - Company Statement: Ipca Laboratories has stated that there will be no material impact on the company’s operations due to this fine. Stay informed on significant legal and regulatory developments impacting the pharmaceutical industry with Global Regulatory Insights. #IpcaLabs #EUCourt #PatentDispute #Pharmaceuticals #CompetitionLaw #GRI
To view or add a comment, sign in
-
In GCR’s Americas Antitrust Review 2025, White & Case’s competition lawyers discuss the latest pharmaceutical antitrust developments, including reverse payment cases, product hopping, and pricing practices. Read more here. https://ow.ly/yKwQ50T23lU
United States: Pharmaceutical Antitrust 2025 | White & Case LLP
whitecase.com
To view or add a comment, sign in